Neuralstem to Expand Pipeline as Part of Aggressive Growth Effort

Neuralstem Appoints Ken Carter, Ph.D., as Executive Chairman of the Board

Neuralstem Reports Third Quarter 2018 Financial Results and Provides Business Update

Neuralstem Announces $2.1 Million Registered Direct Offering

Neuralstem Announces Publication of a Study Showing Benefits of Neural Stem Cell (NSC) Transplantation in a Mouse Model of Alzheimer’s Disease

Neuralstem Provides Business Update and Reports Second Quarter 2018 Fiscal Results

Neuralstem Announces NSI-189 Granted Orphan Drug Designation from the U.S. FDA for the Treatment of Angelman Syndrome

Neuralstem Appoints Jim Scully as Interim Chief Executive Officer

Neuralstem Announces Initiation of Phase 2 Clinical Trial of NSI-566 in Ischemic Stroke

Neuralstem Announces Presentation of Preclinical Data Demonstrating Neurogenic Compound NSI-189 Improves Cognition and Anxiety in a Mouse Model of Alzheimer’s Disease